Abraham Gonzalez, MD
Cardiovascular Disease · El Paso, TXNPI 1578560876
Payments from drug & device makers
Across 28 payments — averaging $587.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Abbott$376
- Inari Medical, Inc.$213
- Biosense Webster, Inc.$186
- Cvrx, Inc.$138
- E.r. Squibb & Sons, L.L.C.$122
- plus $231 from 3 others
What the payments were for
- Grants$15,00091%
- Food & beverage$1,4329%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(3 entities) | 5 | $15,180 |
| Abbott | 5 | $376 |
| Inari Medical, Inc. | 3 | $213 |
| Biosense Webster, Inc. | 2 | $186 |
| Cvrx, Inc. | 2 | $138 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| AbbVie(2 entities) | 8 | $118 |
| Philips North America LLC | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMED$15,000
- Quartet CRT Lead$147
- NUVISION ICE CATHETER$145
- FLOWTRIEVER CATHETER, S$135
- CT THROMBECTOMY SYSTEM KIT$135
- Assurity Pacemaker$127
- Barostim Neo System$123
- CAMZYOS$122
- RESOLUTE ONYX$109
- (9124) LM Undivided$100
How this compares
$16,444 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 268 | $360,591 |
| XareltoRivaroxaban | 143 | $190,354 |
| Repatha SureclickEvolocumab | 37 | $29,883 |
| FarxigaDapagliflozin Propanediol | 31 | $27,194 |
| BrilintaTicagrelor | 22 | $25,652 |
| EntrestoSacubitril/Valsartan | 13 | $19,376 |
| Metoprolol Succinate | 597 | $8,163 |
| Praluent PenAlirocumab | 12 | $5,619 |
| Ranolazine ErRanolazine | 46 | $4,976 |
| Rosuvastatin Calcium | 280 | $4,031 |
| SotalolSotalol Hcl | 133 | $3,918 |
| Labetalol Hcl | 141 | $3,672 |
| Nitroglycerin | 125 | $3,290 |
| Amlodipine Besylate | 446 | $3,191 |
| Losartan Potassium | 313 | $2,717 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in El Paso
- David TurbayEl Paso$1.7M
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.